Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 18/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356500 | 0.93 | SIGMAR1 (0.68) | SIGMAR1ABL1KCNH2MEN1KMT2A | |
| SCHEMBL4654497 | 0.90 | SIGMAR1 (0.56) | SIGMAR1ABL1KCNH2 | |
| SCHEMBL1354942 | 0.83 | SIGMAR1 (0.83) | SIGMAR1KCNH2 | |
| SCHEMBL1354963 | 0.82 | SIGMAR1 (0.60) | SIGMAR1ABL1KCNH2MEN1KMT2A | |
| SCHEMBL1357533 | 0.82 | SIGMAR1 (0.85) | SIGMAR1 | |
| SCHEMBL1356799 | 0.82 | SIGMAR1 (0.85) | SIGMAR1KCNH2 | |
| SCHEMBL467450 | 0.80 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL16339288 | 0.80 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| Hydrochloric Acid SCHEMBL1901550 | 0.80 | SIGMAR1 (0.98) | SIGMAR1KCNH2 | |
| SCHEMBL1356858 | 0.78 | SIGMAR1 (0.64) | SIGMAR1ABL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994008-B1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | ESTEVE LABOR DR (ES) | 2016-08-10 | — | — | EP | claimed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | claimed |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-17 | — | — | US | claimed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | claimed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | claimed |
| EP-1994008-B1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | ESTEVE LABOR DR (ES) | 2016-08-10 | — | — | EP | disclosed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | disclosed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | disclosed |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-17 | — | — | US | disclosed |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-17 | — | — | US | disclosed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | disclosed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | disclosed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | disclosed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | disclosed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | disclosed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | disclosed |
| EP-1994008-A2 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | Laboratorios del Dr. Esteve S.A. (ES) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007098967-A2 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR.ESTEVE, S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885ABL1 452/4885KCNH2 639/4885 |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885ABL1 452/4885KCNH2 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.